Key Highlights
- 157% increase in patient cases processed via Ibex’s AI solution.
- 178% rise in new global customers.
- IVDR certification for prostate, breast, and gastric AI solutions.
- Quest Diagnostics study validates the efficiency of AI-powered workflows.
- Ann Costello joins Ibex’s Board of Directors, adding deep diagnostics expertise.
Source: Business Wire
Notable Quotes
- “Digital pathology has the potential to improve efficiency while saving pathologists valuable time – time they can use to advance patient care through collaboration with colleagues and the multidisciplinary cancer care team.” — Darren Wheeler, MD, VP of Pathology and Medical Services at Quest Diagnostics
- “Securing IVDR certification for our prostate, breast, and gastric diagnostic solutions marks a pivotal achievement for Ibex, highlighting our commitment to superior product quality and innovation in AI-powered diagnostics.” — Joseph Mossel, CEO at Ibex Medical Analytics
SoHC's Take
Ibex Medical Analytics continues to set new benchmarks in the AI-powered cancer diagnostics space. The company’s significant growth in patient case processing and customer acquisition is a clear indicator of the industry’s increasing reliance on AI for enhancing diagnostic accuracy and efficiency. The IVDR certifications and validation through a major study with Quest Diagnostics further underscore Ibex’s commitment to clinical excellence and innovation. With strategic leadership additions and strong financial backing, Ibex is well-positioned to lead the transformation of digital pathology worldwide.
